

# Establishing & Maintaining Data Integrity

## Regulatory Requirements

Gaye Camm

Senior GMP Inspector – Technical Specialist

Inspections Section, Manufacturing Quality Branch

Medical Devices and Product Quality Division, TGA



Australian Government

Department of Health and Aged Care  
Therapeutic Goods Administration

# Acknowledgement of Country

I would like to acknowledge the Traditional Owners and Custodians of the lands on which we meet today and pay my respects to Elders past, present and emerging.

I would like to extend that acknowledgement and respect to any Aboriginal and Torres Strait Islander peoples here today.

---

# Regulatory Requirements

## Manufacturing principles for medicinal products

***PIC/S Guide to Good Manufacturing Practice for Medicinal Products, PE009-15, 01 May 2021 (PE009-15)***

Data integrity in the pharmaceutical sciences

- Computers
- Software
- Electronic data

...used throughout the manufacture, testing and documentation of therapeutic goods

# What is Data Integrity?

The degree to which data are

- Complete
- Consistent
- Accurate
- Trustworthy
- Reliable

...and these characteristics of the data are maintained through the data life cycle



PHARMACEUTICAL INSPECTION CONVENTION  
PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME

PI 041-1  
1 July 2021

PIC/S GUIDANCE

**GOOD PRACTICES FOR DATA  
MANAGEMENT AND INTEGRITY IN  
REGULATED GMP/GDP  
ENVIRONMENTS**

© PIC/S 2021  
Reproduction prohibited for commercial purposes.  
Reproduction for internal use is authorised,  
provided that the source is acknowledged.


Editor: PIC/S Secretariat

e-mail: [info@picscheme.org](mailto:info@picscheme.org)

web site: <https://www.picscheme.org>

<https://picscheme.org/docview/4234>

# ALCOA+ Principles



# Regulatory Requirements

## ALCOA+ principles vs. PIC/S Guide to GMP


ALCOA principle	PIC/S Guide to GMP Part I	PIC/S Guide to GMP Part II	Annex 11 (Computerised Systems)
Attributable	[4.20, c & f], [4.21, c & i], [4.29 point 5]	[5.43], [6.14], [6.18], [6.52]	[2], [12.1], [12.4], [15]
Legible	[4.1], [4.2], [4.7], [4.8], [4.9], [4.10]	[6.11], [6.14], [6.15], [6.50]	[4.8], [7.1], [7.2] [8.1], [9], [10], [17]
Contemporaneous	[4.8]	[6.14]	[12.4], [14]
Original	[4.9], [4.28]	[6.14], [6.15], [6.16]	[8.2], [9]

## ALCOA+ principles vs. PIC/S Guide to GMP (cont.)

ALCOA principle	PIC/S Guide to GMP Part I	PIC/S Guide to GMP Part II	Annex 11 (Computerised Systems)
Accurate	[4.1], [6.17]	[5.40], [5.42], [5.45], [5.46], [5.47], [6.6]	[Paragraph "Principles"] [4.8], [5], [6], [7.2], [10], [11]
Complete	[4.8]	[6.16], [6.50], [6.60], [6.61]	[4.8], [7.1], [7.2], [9]
Consistent	[4.2]	[6.15], [6.50]	[4.8], [5]
Enduring	[4.1], [4.10]	[6.11], [6.12], [6.14]	[7.1], [17]
Available	[Paragraph "Principle"], [4.1]	[6.12], [6.15], [6.16]	[3.4], [7.1], [16], [17]


# Creating the right environment

- Data management controls embedded in PQS
  - System design to ensure good DI practices
  - QRM approach to data integrity
  - Ongoing risk review of data criticality vs. risk
  - Robust self inspection program
- Clear understanding of importance of data integrity at all levels of the organisation
- Internal reporting encouraged & supported by Management
- Mature, open management approach to data integrity





# Risk management approach to Data Integrity



- Data Criticality
  - Batch release data > cleaning records
  - Data relating to product quality/safety
- Data Risk
  - Vulnerability of data to alteration, deletion, recreation, loss or deliberate falsification

Desired outcome = effective control strategy to manage identified risks

# Where does it go wrong?

## Data integrity issues seen during TGA inspections

*Deficiencies relating to data integrity failure may have varying impact to product quality. Prevalence of the failure may also vary between the actions of a single employee to an endemic failure throughout the inspected organisation.*

*- PIC/S guidance - PIC/S Good Practices for Data Management and Integrity PI 041*



*Annex 11 §4.3 An up-to-date listing of all relevant systems and their GMP functionality (inventory) should be available. For critical systems, an up-to-date system description detailing the physical and logical arrangements, data flows and interfaces with other systems or processes, any hardware and software pre-requisites, and security measures should be available.*



- No consolidated listing available
- Missing information e.g. PLC controlled equipment, simple testing instruments such as auto titrators, pH meters.
- Interfaces with other systems or processes not documented

# Examples of critical systems

## Questions to consider


- Does the system control the purchasing and/or status of products and materials?
- Is it used for the control and data acquisition for critical manufacturing processes or testing activities?
- Does the system generate, store or process data that is used to determine batch quality?
- Will the system generate data that is included in the batch processing or packaging records?
- Is the system used in the decision process for the release of products?
- Do you have simple systems that generate initial records in electronic format?

## Computerised system should be verified for intended use



- No URS available for newly installed computerised systems
- Documentation supplied with commercial off-the-shelf products not reviewed to ensure user requirements are fulfilled
- Validation reports for critical system contained inadequate system descriptions:
  - data flows and interfaces with other systems or processes
  - hardware and software pre-requisites
  - security measures required for DI

# Laboratory Electronic systems





## Control of standalone systems



- Back up of electronic data poorly administered
- Unique user logins not implemented for all staff
- Time & date on computer can be modified by user
- Data can be deleted directly from hard drives without detection

*Annex 11 §9: Consideration should be given, based on a risk assessment, to building into the system the creation of a record of all GMP-relevant changes and deletions (a system generated "audit trail"). For change or deletion of GMP-relevant data the reason should be documented. Audit trails need to be available and convertible to a generally intelligible form and regularly reviewed.*



- Audit trail not regularly reviewed
- Audit trail review conducted on select data only
- Review requirements not formalised in procedures
- Orphan data not captured in analysis
- Reconciliation of electronic data with associated logbooks not considered



## Third party suppliers of cloud services



- No risk assessment conducted to identify risk associated with using third parties who are creating, processing or storing regulated data
- No supplier assessment of cloud service providers conducted
- No formal agreement in place between the manufacturer and cloud service provider outlining GMP responsibilities

# TGA expectations...understand vulnerabilities

- Design systems to prevent DI issues
- Ensure the data is authentic and retrievable
- Train staff and encourage correct behaviours and practices
- Open communication
- Encourage feedback
- System for ongoing review
  
- It's not someone else's problem





# Questions?

[www.tga.gov.au](http://www.tga.gov.au)



**Australian Government**

---

**Department of Health and Aged Care**  
Therapeutic Goods Administration